Natalizumab to fingolimod washout in patients at risk of PML

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neurology

• Publication date

  2014-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0000000000000296PMID 24610331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

  2016cited by this paper
• Fingolimod after natalizumab and the risk of short-term relapse

  2014cited by this paper
• Reduction of the washout time between natalizumab and fingolimod

  2013cited by this paper
• Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO)

  2013cited by this paper
• Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring

  2012influential reference
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings

  2012cited by this paper
• Increasing age at disability milestones among MS patients in the MSBase Registry.

  2012cited by this paper
• Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

  2011cited by this paper
• Interruption of natalizumab therapy for multiple sclerosis

  2011cited by this paper
• The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

  2011cited by this paper
• Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

  2011cited by this paper
• Natalizumab: bound to rebound?

  2009cited by this paper
• Is natalizumab overshooting its rebound?

  2008cited by this paper
• POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS

  2008cited by this paper
• Update. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.

  2008cited by this paper
• MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

  2006cited by this paper

• Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design

  2024cites this paper
• Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.

  2020cites this paper
• Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.

  2019cites this paper
• Editors' Welcome.

  2017cites this paper
• The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies.

  2017cites this paper
• The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations

  2017cites this paper
• Update on disease-modifying therapies for multiple sclerosis

  2017cites this paper
• Pattern Recognition of the Multiple Sclerosis Syndrome

  2017cites this paper
• Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events

  2017cites this paper
• Switching patients at high risk of PML from natalizumab to another disease-modifying therapy

  2016cites this paper
• Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis

  2016influential citation
• Aktuelles zur Therapieumstellung bei Multipler Sklerose

  2015cites this paper
• Aktuelles zur Therapieumstellung bei Multipler Sklerose

  2015cites this paper
• An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations

  2015cites this paper
• Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis

  2015cites this paper
• Lack of Major Histocompatibility Complex Class I Upregulation and Restrictive Infection by JC Virus Hamper Detection of Neurons by T Lymphocytes in the Central Nervous System

  2015cites this paper
• Advances in the management of relapsing–remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)

  2015cites this paper